Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series

• DOI: 10.1186/s12894-015-0102-x
• Publication Date: 2015-10-23T22:39:14Z
• Authors: Daniel S. Engeler; Daniel Meyer; Dominik Abt; Stefanie Müller; Hans-Peter Schmid
• Keywords: Neuromodulation; Refractory (planetary science); Upper urinary tract

Sacral neuromodulation is well established in the treatment of refractory, non-neurogenic lower urinary tract dysfunction, but its efficacy and safety patients with dysfunction neurological origin unclear. Only few case series have been reported for multiple sclerosis. We prospectively evaluated sacral Seventeen (13 women, 4 men) treated refractory neurogenic caused by sclerosis were enrolled (2007–2011). Patients had to stable disease confirmed dysfunction. Voiding variables, adverse events, subjective satisfaction assessed. Sixteen (94 %) a positive test phase >70 % improvement. After implantation pulse generator (InterStim II), improvement voiding variables persisted. At 3 years, median voided volume improved significantly from 125 (range 0 350) 265 ml 200 (p < 0.001), post void residual 170 730) 25 300) = 0.01), micturition frequency 12 6 20) 7 12) 0.003), number incontinence episodes 10) 1) 0.006). The degree was 80 %. two developed lack benefit. No major complications occurred. Chronic promises be an effective safe selected